EP Patent

EP2069374B2 — Crystalline solvates of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with alcohols as sglt2 inhibitors for the treatment of diabetes

Assigned to AstraZeneca AB · Expires 2021-07-28 · 5y expired

What this patent protects

Patent listed against Farxiga.

Drugs covered by this patent

Patent Metadata

Patent number
EP2069374B2
Jurisdiction
EP
Classification
—
Expires
2021-07-28
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.